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Epidennolytic palmoplantar keratodenna is an auto-
somal dominant skin disorder characterized by hy-
perkeratosis of the palms and soles. Ultrastructurally 
the disease exhibits abnonnal keratin filament net-
works and tonofilament clumping like that found in 
the keratin disorders of epidennolysis bullosa sim-
plex and epidennolytic hyperkeratosis. The disease 
has been mapped to chromosome 17q11-q23 in the 
region of the type 1 keratin gene locus and more 
recently mutations have been found in the palmo-
plantar specific keratin, keratin 9. We have analyzed 
six unrelated incidences of epidermolytic palmoplan-
tar keratodenna for mutations in their keratin 9 
genes. In two of these, we have identified mutations 
that alter critical residues within the highly con-
pidermolytic palmoplantar keratoderma (EPPK) is an 
autosomal dominant genodermatosis (MIM number 
144200 [1]) first described by Vomer in 1901 [2]. It is 
characterized by a diffuse thickening of palmar and 
....... plantar epidermis that first becomes apparent shortly 
after birth (reviewed in [3]). Eventually these surfaces are covered 
by thick hyperkeratotic plates that are yellow-brown in color. The 
keratoderma is sharply defined with a distinctive erythematous 
border at the wrists and ankles [4]. In some patients, keratodermic 
islands cover the knuckles but the remaining aspects of the dorsal 
surfaces of the hands and feet are never involved. Patients complain 
of increased sensitivity of their palm and soles to mechanical insult 
resulting in fissuring, particularly at the joints. Scaling, blistering, 
and erosions are not common but may be present at the margins 
[5,6]. Histopathology is characterized by a marked expansion of the 
granular and stratum corneum layers [5-9]. Keratinocytes of the 
upper spinous and granular layers of affected areas show perinuclear 
vacuolization and cytolysis with abnormal keratohyalin granules. 
Ultrastructural analysis of these cells reveals the presence of 
abnormal keratin filaments and tonofilament clumping often with a 
perinuclear distribution [5-9]. 
The similarity of these ultrastructural features to those of the 
known keratin disorders of epidermolysis bullosa simplex (EBS) 
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served helix initiation motif at the beginning of the 
rod domain of keratin 9. In a three-generation Middle 
Eastern kindred we found a C to T transition at codon 
162 that results in an arginine to tryptophan substi-
tution at position 10 of the 1A alpha-helical domain, 
thus confinning this codon as a hot spot for mutation 
in keratin 9. The other mutation found involves a T 
to C transition at codon 167 that results in the 
expression of a serine residue in place of the nonnal 
leucine at position 15 of the 1A segment and is the 
first documentation of this mutation in this gene. 
The identification of these substitutions extends the 
current catalog of disease causing mutations in ker-
atin 9. Key words: intermediate filaments/disease/genetics. 
] Invest Dermatol 104:430-433, 1995 
and epidermolytic hyperkeratosis (EHK) [10], together with its 
dominant mode of inheritance, suggested that EPPK is also caused 
by a keratin defect. Earlier linkage analyses mapped the candidate 
gene for EPPK to chromosome 17q11-q23 [11], in the region of the 
type 1 keratin gene cluster. Of the type 1 keratins, only keratin 9 
(K9) has been shown to be expressed exclusively in the epidermis 
of palms and soles [12]. On this basis, K9 was proposed as the 
candidate gene for EPPK and recently mutations in the K9 gene 
have been identified in EPPK patients [13-16].§~ All of these 
mutations have been found within the first alpha-helical segment of 
K9. Here we report two more incidences of EPPK bearing muta-
tions within the helix initiation motif at the beginning of the rod 
domain of K9. 
MA TERlALS AND METHODS 
PCR and DNA Sequencing Genomic DNA was extracted and purified 
from whole blood as described previously [17]. At the time that these 
studies were initiated, the K9 gene sequence was unavailable. Therefore 
genomic sequence analysis was performed using oligonucleotide primers 
designed from the cDNA sequence [18]. The primers used to amplify ex on 
1, which contains the 1A region, including the highly conserved RLASYL 
motif, were 5' -CTCAACCCGTGAGCT ACCAGCTGTG-3' and 5' -GAT-
AGCAGCAGGTCCCTTCTTGTCG-3' corresponding to bp 40-64 and to 
630-654 of the published sequence [18]. The 5 ' oligonucleotide was 
biotinylated to facilitate the purification of single- stranded DNA for se-
§ Bowden PE, Watts CE, Marks R: Mutation of human keratin 9 (HK9) 
gene in epidermolytic tylosis (abstr).] Invest Dermatoll02:541, 1994. 
~ Shamsher M, Navsaria HA, Ratnavel R, McLean I, Lane EB, Griffiths 
~T AD, Leigh 1M: Mutation of keratin 9 gene in epidermolytic palmoplantar 
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quencing [19]. The sequence primer used was 5'-CTTGTCGTACCAATC-
CTG-3' corresponding to bp 619-636 of the published sequence [18]. 
Polymerase chain reactions (PCR) were preheated at 95°C for 5 min prior 
to the addition of 1 U ofTaq DNA polymerase (AmpliTaq, Perkin-Elmer). 
Amplification conditions consisted of 30 cycles of 1 min at 94°C, 2 min at 
55°C, and 3 min at noc and a final elongation step of15 min at n°c. PCR 
products were first-column purified (Magic PCR Preps, Promega) and the 
biotinylated DNA strands were captured on streptavidin-coated magnetic 
beads (Dynal) and directly sequenced using Sequenase T7 DNA polymerase 
(US Biochemicals). The reaction products were separated on 6% acrylamide 
denaturing gels. 
As-peR Analysis Allele-specific PCR was performed using a primer 
specific for the T to C mutation at bp 566. The primer used was 
5'-TAGAGCCTGCACCTTATCCG-3', corresponding to bp 566-585 of 
the published eDNA sequence [18], and was paired with the 5' biotinylated 
primer used for generating the sequencing template. PCR conditions 
consisted of 95°C for 5 min followed by 35 cycles of30 seconds at 94°C, 1 
min at 64°C, and 3 min at 68°C, and a final elongation step of 15 min at 
72°C. PCR products were visualized on a 1 % agarose gel. A fragment of 
545 bp was generated in the presence of the mutant nucleotide. 
RESULTS 
Clinical Description of the EPPK Patients The EPPK-I1D 
family (Fig 1) is of Middle Eastern heritage. All affected family 
members (1.1, II.2, II.4, II.5, and IIl.l) show a similar clinical 
picture with diffuse thickening of palmar and plantar surfaces 
characterized by a yellow-brown hyperkeratosis with fissuring 
occurring mainly at the joints. There is some involvement of the 
dorsal surfaces, predominantly over the joints of the fingers and to 
a lesser extent of the toes. No other skin alterations were found, 
and the other structures of the integument, such as nails, hair, and 
teeth, were all normal. There was no hyperhidrosis and no evidence 
of deafuess or mental retardation. Onset of the disease in all patients 
was within the first weeks after birth. All patients report exacerba-
tion of the disease with blister formation and subsequent macera-
tion (infection) after mechanical trauma. Histopathology revealed 
hyperkeratosis with acanthosis and epidermolysis. The EPPK-S 
family (Fig 1) is African-American. The proband is a 4-year-old 
boy (11.1). The skin of his palms and soles appeared normal up to 
the age of approximately 3 months, when thickening and roughness 
of his palms and soles were first noticed. He now exhibits thick 
hyperkeratotic plaques on his palms and soles with some scaling. 
EPPK- IJD 
I 
II 
2 3 4 5 
ill 
EPPK- S 
I 
2 
II 
Figure 1. Pedigrees of the EPPK families. Solid symbols, affected 
individuals; open symbols, unaffected; squares, male; circles, female. 
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There was no involvement of the nails. A biopsy from the palm 
showed histologic features of epidermolysis and hyperkeratosis. 
The mother stated that his lesions were very similar to ones present 
on the father's side of the family. The father was not available for 
clinical examination. Family history is remarkable according to the 
mother for an affected father, an affected paternal grandfather, a 
paternal great aunt, and possibly a distant cousin with similar 
physical findings. 
Sequence Analysis of K9 We analyzed the K9 gene for 
mutations in six unrelated incidences of EPPK. Because all previ-
ously described keratin mutations have been found in the H1, lA, 
L12, and 2B regions of these proteins (see [20,21] for a review), we 
focused our analysis on these regions of the K9 gene. Primer pairs 
were chosen to amplify the amino-terminal end ofK9 including the 
lA segment of the rod domain, the carboxyl-terminal end of the 2B 
segment and a fragment that included the L12 linker, the 2A 
segment, and the L2 linker. Sequence analysis of these PCR-
generated fragments revealed a mutation in the 1A region of the K9 
gene in two of the six EPPK families. Affected individuals of the 
EPPK-I1D family have a mutation of the highly conserved arginine 
residue at position 10 of the rod domain. The C to T transition at 
bp 550 in these patients results in an arginine (R) to tryptophan (W) 
substitution (Fig 2a). The affected individual of the EPPK-S family 
carries a T to C transition at bp 566, resulting in a leucine (L) to 
serine (S) substitution at residue 15 of the lA segment (Fig 2b). In 
both families the mutations were only present in affected individ-
uals. To insure that these mutations were not spurious alterations 
introduced by the polymerase chain reaction, each reaction was 
repeated and sequenced independently. Apart from these mutations 
no other substitutions were observed in the Hl, lA, L12, and 2B 
regions of K9 in the six patients analyzed. A sequence polymor-
phism (A-C) was observed in the Vl region at bp 492 in both 
affected and unaffected individuals; however, this base substitution 
affects the third position of a glycine codon and does not result in 
an amino acid change. This inconsequential polymorphism was also 
detected in the study by Reis et al [13] and found to occur 
frequently. 
Mutation Analysis Further analysis of the T to C mutation at bp 
566 was undertaken to exclude the possibility that this base change 
is present in the normal population as a silent polymorphism. 
Because this mutation did not create or destroy a restriction enzyme 
site, we used an oligonucleotide primer specific for this substitution 
to assess its presence in the DNA of 50 unrelated control individuals 
using allele-specific PCR (AS-PCR). The 545-bp fragment present 
in the affected individual of the EPPK-S family was not observed in 
these normal DNAs (Fig 3 and data not shown). 
DISCUSSION 
In this study we have identified mutations of two critical residues 
within the helix initiation motif of K9 in EPPK patients, a highly 
conserved arginine residue at position 10 of the lA segment and a 
leucine residue at position 15 at the end of the helix initiation motif. 
The helix initiation motif comprises the first 15 residues of the lA 
segment and is highly conserved in all intermediate filament types 
[22]. A number of recent studies have shown that these residues are 
important for filament assembly and stability and are thought to be 
involved in lateral associations with residues of the TYRXLLEGE 
motif at the end of the 2B segment of neighboring coiled-coil 
molecules [23]. It is also apparent from both in vitro analyses [24,25] 
and patient studies [21] that mutations in these conserved sequences 
at the ends of the rod domain are more deleterious in terms of 
filament disruption and phenotypic severity tha:n those occurring at 
internal residues. Significantly, most of the keratin mutations 
identified to date affect residues of the helix initiation motif with 
almost 50% involving the arginine residue at position 10 of the type 
I keratins [21]. 
The availability of the nucleotide sequence for K9 has enabled 
direct sequence analysis of the gene in EPPK patients. Previous to 
this study, seven different point mutations resulting in substitutions 
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Figure 2. Genomic sequence analysis of the 1A region ofK9 from individuals affected with EPPK. Normal, sequence obtained from an unaffected 
family member. Hetero, sequence from an affected individual who carries the mutation and is therefore heterozygous for the K9 allele. Numbering of the 
amino acids is with respect to the lA segment of the rod domain. a) Sequence from members of the EPPK-I1D family. Affected individuals show a C to T 
transition, resulting in the expression of a tryptophan residue (W) at position 10. b) Sequence from the EPPK-S family. The affected individual shows a T 
to C transition that results in a leucine (L) to serine (S) substitution at residue 15 of the lA segment. Residues 10 and 15 correspond to codons 162 and 167 
respectively, of the published K9 sequence [17]. 
within the 1A segment of K9 had been identified [13-16].§~ The 
R10W substitution identified in this study was detected in five 
unrelated German kindreds by Reis et al [13]. Haplotype analysis of 
these families could not rule out the possibility of a common origin, 
i.e., a founder effect, for some of these patients [13]. Therefore, our 
finding of the same mutation in a family with a different ethnic 
origin supports the thesis that this arginine codon is a hot spot for 
mutation in the K9 gene [13],just as it is for the K10 and K14 genes 
[26,27]. In fact during the course of these studies, a further three 
R10W substitutions in K9 from EPPK patients were reported~ [16] 
making a total of ten incidences found to date involving mutation 
of this arginine residue. The L15S substitution found in the EPPK-S 
family is the first report of this mutation in K9, although the same 
substitution has been identified in K10 in an EHK family [17]. 
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Figure 3. AS-PCR analysis of the T to C transition at bp 566. 
Genomic DNAs from 50 unrelated control individuals as well as the normal 
mother and affected son of the EPPK-S family were analyzed for the 
presence of a cytosine at bp 566. Lanes: M, 0X174/Hae III markers; 1, 
affected individual (11.1 of EPPK-S); 2, unaffected individual (1.11 of 
EPPK-S); 3-7, representative sample of unrelated and unaffected individu-
als. 
Functional data showing that the K9 mutations identified in this 
study are causal for the disease remain to be unequivocally estab-
lished through transgenic studies. However, a number of in vitro 
studies, where mutant intermediate filament proteins have been 
introduced into cultured cells, have implicated the arginine residue 
at position 10 of the 1A segment as critical to filament integrity 
[28,29]. Furthermore, an in vitro filament disassembly assay deter-
mined that non-conservative substitutions, of the arginine at posi-
tion 10 and the leucine at position 15 of the 1A region (including 
the serine substitution), were not tolerated in terms of their ability 
to interact with wild-type intermediate filaments [30]. The arginine 
residue at position 10 of the 1 A segment is conserved in 47 of 51 
published IF protein sequences [22,29], and the leucine at position 
15 is completely conserved in all type I keratins and conservatively 
substituted (isoleucine) in type II keratins and other IF proteins 
[22]. The high degree of conservation of the R10 and the L15 
residues suggest that few, if any, changes of these residues are 
tolerated and underscores the importance of their respective side-
chains to filament biology. Tn addition, the lack of polymorphic 
variation in these sites in unaffected individuals strongly suggests 
that the two K9 mutations identified in this study do in fact cause 
EPPK. 
The residues in the a and d positions of the 7 residue repeat 
making up the alpha-helical forming sequences of intermediate 
filament proteins are the most highly conserved, followed by the 
residues of the e and g positions [22]. Residues of the a, d, e, and 
g positions are sited on the internal face of the helix and are 
positioned to interact (via hydrophobic and ionic bridges) with 
residues on the neighboring helix of the two-chain coiled-coil 
complex. It is not surprising then that these positions should be the 
most sensitive to disease causing substitutions [21]. The R10W and 
L15S substitutions in the helix initiation motif ofK9 occur at g and 
e positions, respectively. In case of the arginine to tryptophan 
substitution at position 10 both the charge and shape of the side 
chain are altered, whereas in the leucine to serine substitution the 
change remains neutral but both the hydrophobicity and size of the 
side chain at position 15 are altered. Since the residues at e and g 
positions are thought to contribute to higher-order interactions, 
both substitutions can be expected to perturb the function of the 
VOL. 104, NO.3 MARCH 1995 
helix initiation motif and thereby disrupt the keratin-filament 
cytoskeleton. 
It is noteworthy that we were unable to identify mutations within 
the highly conserved regions of the rod domain ofK9 in four of the 
EPPK families studied. It is possible that affected individuals of these 
families bear mutations elsewhere in the rod domain of K9 at 
residues not previously associated with disease-forming substitu-
tions. However, it should be noted that in the studies by Reis and 
colleagues [13,15] nearly half of the EPPK probands analyzed did 
not carry a mutation in their K9 genes. Similar observations have 
been reported for the other keratin disorders of EBS and EHK. 
About 25% ofEHK patients do not harbor mutations in their K1 or 
K10 genes and we have shown recently that some of these 
individuals actually carry mutations within their K2e genes [31], 
suggesting the possibility of other keratin genes being involved in 
EPPK. Both EBS and EHK can be caused by mutations in either of 
two keratin chains making up the mature filament. The natural type 
II partner of K9 has yet to be identified but, because over half of 
EPPK families analyzed to date do not carry K9 mutations, it seems 
likely that they harbor a mutation in a type II keratin. To date a type 
II keratin with expression limited to palms and soles has yet to be 
identified. It is possible, however, that these EPPK patients bear 
mutations in the more ubiquitous type II keratins such as K1 and 
K2e, which only manifest themselves in disease at sites of constant 
and prolonged mechanical stress. Because the hands and feet are the 
surfaces most prone to these forces, expression of disease would 
appear limited to these regions. An analogous situation has already 
been shown with the K5 and K14 mutations found in EBS-Weber-
Cockayne patients [32]. Other candidate keratin genes include K6 
and K16 whose expression is normally limited to palmar and plantar 
epidermis and the outer root sheath of the hair follicle [33]. Finally, 
the proteins that associate or otherwise interact directly with the 
keratin filament cytoskeleton should not be overlooked as possible 
sites of disease causing mutations in these patients. 
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